Literature DB >> 14692693

Phosphodiesterases in the vascular system.

Takayuki Matsumoto1, Tsuneo Kobayashi, Katsuo Kamata.   

Abstract

Cyclic adenosine 3',5'-monophosphate (cAMP) and cyclic guanosine 3',5'-monophosphate (cGMP) are second messengers involved in the intracellular signal transduction of a variety of extracellular stimuli in several tissues. In the vascular system, these nucleotides play important roles in the regulation of vascular tone and in the maintenance of the mature contractile phenotype in smooth muscle cells. Given that cyclic nucleotide signaling regulates a wide variety of cellular functions, it is not surprising that cyclic nucleotide phosphodiesterases (PDEs). In paticular, the accumulating data showing that there are a large number of different PDE isozymes have triggered an equally large increase in interest about these enzymes. At least 11 different gene families of PDEs are currently known to exist in mammalian tissues. Most families contain several distinct genes, and many of these genes are expressed in different tissues as functionally unique alternative splice variants. This article reviews many of the important aspects about the structure, cellular localization, and regulation of each family of PDEs. Particular emphasis is placed on new information obtained in the last few years about vascular disease. The development of novel methods to deliver more potent and selective PDE inhibitors to individual cell types and subcellular locations will lead to new therapeutic uses for this class of drugs in diseases of the vascular system.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14692693     DOI: 10.1540/jsmr.39.67

Source DB:  PubMed          Journal:  J Smooth Muscle Res        ISSN: 0916-8737


  13 in total

1.  Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP.

Authors:  Mingyi Yao; David D Roberts; Jeff S Isenberg
Journal:  Pharmacol Res       Date:  2010-10-29       Impact factor: 7.658

2.  Phosphodiesterase 3A expression is modulated by nitric oxide in rat pulmonary artery smooth muscle cells.

Authors:  C J Busch; A R Graveline; K Jiramongkolchai; H Liu; L S Sanchez; K D Bloch
Journal:  J Physiol Pharmacol       Date:  2010-12       Impact factor: 3.011

3.  PDE1A inhibition elicits cGMP-dependent relaxation of rat mesenteric arteries.

Authors:  Makhala Michell Khammy; Thomas Dalsgaard; Peter Hjørringgaard Larsen; Claus Tornby Christoffersen; Dorte Clausen; Lars Kyhn Rasmussen; Lasse Folkersen; Morten Grunnet; Jan Kehler; Christian Aalkjaer; Jacob Nielsen
Journal:  Br J Pharmacol       Date:  2017-10-15       Impact factor: 8.739

4.  UCR1C is a novel activator of phosphodiesterase 4 (PDE4) long isoforms and attenuates cardiomyocyte hypertrophy.

Authors:  Li Wang; Brian T Burmeister; Keven R Johnson; George S Baillie; Andrei V Karginov; Randal A Skidgel; John P O'Bryan; Graeme K Carnegie
Journal:  Cell Signal       Date:  2015-02-12       Impact factor: 4.315

5.  Role of endothelium-dependent hyperpolarisation and prostacyclin in diabetes.

Authors:  Siti Safiah Mokhtar; Aida Hanum Ghulam Rasool
Journal:  Malays J Med Sci       Date:  2015 Mar-Apr

6.  Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes.

Authors:  Styliani Goulopoulou; Johanna L Hannan; Takayuki Matsumoto; Safia Ogbi; Adviye Ergul; R Clinton Webb
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-05-08       Impact factor: 4.733

7.  Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation.

Authors:  Gaby Wangorsch; Elke Butt; Regina Mark; Katharina Hubertus; Jörg Geiger; Thomas Dandekar; Marcus Dittrich
Journal:  BMC Syst Biol       Date:  2011-10-28

8.  Effect of sildenafil on neuropathic pain and hemodynamics in rats.

Authors:  Lan Ji Huang; Myung Ha Yoon; Jeong Il Choi; Woong Mo Kim; Hyung Gon Lee; Yeo Ok Kim
Journal:  Yonsei Med J       Date:  2009-12-29       Impact factor: 2.759

9.  Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver.

Authors:  Leonie Halverscheid; Peter Deibert; René Schmidt; Hubert E Blum; Torsten Dunkern; Benedikt H J Pannen; Wolfgang Kreisel
Journal:  BMC Gastroenterol       Date:  2009-09-18       Impact factor: 3.067

Review 10.  Treating COPD with PDE 4 inhibitors.

Authors:  William M Brown
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.